MRI-based radiomic features for identifying recurrent prostate cancer after proton radiation therapy
CONCLUSIONS: Our proof-of-concept study demonstrates the potential of using radiomic features as part of the differential diagnosis of PCa on mpMRI following proton therapy. The results need to be validated in a larger cohort.PMID:38409947 | DOI:10.1002/acm2.14293 (Source: Clinical Prostate Cancer)
Source: Clinical Prostate Cancer - February 27, 2024 Category: Cancer & Oncology Authors: Kazim Z Gumus Samuel Serrano Contreras Mohammed Al-Toubat Ira Harmon Mauricio Hernandez Savas Ozdemir Sindhu Kumar Nurcan Yuruk Mutlu Mete K C Balaji Mark Bandyk Dheeraj R Gopireddy Source Type: research
Radical prostatectomy cancer grade and percentage of Gleason pattern 4 estimated by global vs individual tumor grading correlate differently with the risk of biochemical recurrence in Grade Group 2 and 3 cancers
CONCLUSIONS: Grade Group, GP4%, and margin status derived by global vs individual tumor grading predict postoperative biochemical recurrence statistically significantly differently. This difference has important implications if results derived from cohorts graded using different methods are compared.PMID:38412318 | DOI:10.1093/ajcp/aqae003 (Source: Clinical Prostate Cancer)
Source: Clinical Prostate Cancer - February 27, 2024 Category: Cancer & Oncology Authors: Oleksandr N Kryvenko Jonathan I Epstein Ali Merhe Oleksii A Iakymenko Ricardo De Almeida E Silva Dimple Kumar Chanamolu Laurence M Briski Deukwoo Kwon Ivan Nemov Sanoj Punnen Alan Pollack Radka Stoyanova Dipen J Parekh Merce Jorda Mark L Gonzalgo Source Type: research
Splicing targeting drugs highlight intron retention as an actionable vulnerability in advanced prostate cancer
CONCLUSIONS: Our study uncovers intron retention as an actionable vulnerability for advanced PC, which may be exploited to improve therapeutic management of this currently incurable disease.PMID:38413979 | PMC:PMC10898177 | DOI:10.1186/s13046-024-02986-0 (Source: Clinical Prostate Cancer)
Source: Clinical Prostate Cancer - February 27, 2024 Category: Cancer & Oncology Authors: Chiara Naro Ambra Antonioni Vanessa Medici Cinzia Caggiano Ariane Jolly Pierre de la Grange Pamela Bielli Maria Paola Paronetto Claudio Sette Source Type: research
Cutaneous Metastasis From Prostate Cancer on Posttherapeutic 177Lu-Prostate-Specific Membrane Antigen Scan
Clin Nucl Med. 2024 Feb 27. doi: 10.1097/RLU.0000000000005130. Online ahead of print.ABSTRACTIn this note, we aim to present a patient with a known case of prostate cancer with widespread metastasis to the skeleton and liver who has undergone several cycles of chemoradiotherapy. The patient received 2 doses of 177Lu-prostate-specific membrane antigen therapy, in which several zones of uptake were detected on the thoracic wall compatible with cutaneous metastatic lesions of prostate cancer.PMID:38409757 | DOI:10.1097/RLU.0000000000005130 (Source: Clinical Prostate Cancer)
Source: Clinical Prostate Cancer - February 27, 2024 Category: Cancer & Oncology Authors: Mohammad Taghavi Reyhane Ahmadi Mohsen Qutbi Source Type: research
68Ga-PSMA Uptake in the Testis: Two Different Patients With Two Different Diagnosis
Clin Nucl Med. 2024 Feb 27. doi: 10.1097/RLU.0000000000005128. Online ahead of print.ABSTRACTAlthough abnormal 68Ga-PSMA uptake in the prostate and its metastases can be seen in a variety of diseases, it is rare to see in the testis. In these 2 cases, 68Ga-PSMA PET/CT revealed unilateral 68Ga-PSMA uptake in the testis of 2 patients. One of these patients was diagnosed with testis metastases from prostate cancer after an orchiectomy. The other patient was diagnosed with an orchitis. 68Ga-PSMA uptake should be considered as an infection, as well as a malignancy in the initial differential diagnosis.PMID:38409760 | DOI:10.109...
Source: Clinical Prostate Cancer - February 27, 2024 Category: Cancer & Oncology Authors: Merve Nida Calderon Tobar Hasan Önner Source Type: research
Dual 177Lu-Prostate-Specific Membrane Antigen and 177Lu-DOTATATE Therapy in Metastatic Castration-Resistant Prostate Cancer With Neuroendocrine Differentiation
We present an 87-year-old man diagnosed with prostate cancer and neuroendocrine differentiation, posttherapy results to consecutive 177Lu-prostate-specific membrane antigen and 177Lu-DOTATATE. Despite hormonal therapy and chemoradiotherapy, the patient progressed rapidly, and multiple liver and bone metastases showed regression after 177Lu-prostate-specific membrane antigen and 177Lu-DOTATATE treatment. Prostate cancer with neuroendocrine differentiation is resistant to treatments; however, treatment with the combination of 177Lu-DOTATATE therapy may be promising.PMID:38409763 | DOI:10.1097/RLU.0000000000005131 (Source: Cl...
Source: Clinical Prostate Cancer - February 27, 2024 Category: Cancer & Oncology Authors: Ediz Beyhan Özge Erol Fenercioğlu Rahime Şahin Tevfik Fikret Çermik Nurhan Erg ül Source Type: research
MRI-based radiomic features for identifying recurrent prostate cancer after proton radiation therapy
CONCLUSIONS: Our proof-of-concept study demonstrates the potential of using radiomic features as part of the differential diagnosis of PCa on mpMRI following proton therapy. The results need to be validated in a larger cohort.PMID:38409947 | DOI:10.1002/acm2.14293 (Source: Clinical Prostate Cancer)
Source: Clinical Prostate Cancer - February 27, 2024 Category: Cancer & Oncology Authors: Kazim Z Gumus Samuel Serrano Contreras Mohammed Al-Toubat Ira Harmon Mauricio Hernandez Savas Ozdemir Sindhu Kumar Nurcan Yuruk Mutlu Mete K C Balaji Mark Bandyk Dheeraj R Gopireddy Source Type: research
Radical prostatectomy cancer grade and percentage of Gleason pattern 4 estimated by global vs individual tumor grading correlate differently with the risk of biochemical recurrence in Grade Group 2 and 3 cancers
CONCLUSIONS: Grade Group, GP4%, and margin status derived by global vs individual tumor grading predict postoperative biochemical recurrence statistically significantly differently. This difference has important implications if results derived from cohorts graded using different methods are compared.PMID:38412318 | DOI:10.1093/ajcp/aqae003 (Source: Clinical Prostate Cancer)
Source: Clinical Prostate Cancer - February 27, 2024 Category: Cancer & Oncology Authors: Oleksandr N Kryvenko Jonathan I Epstein Ali Merhe Oleksii A Iakymenko Ricardo De Almeida E Silva Dimple Kumar Chanamolu Laurence M Briski Deukwoo Kwon Ivan Nemov Sanoj Punnen Alan Pollack Radka Stoyanova Dipen J Parekh Merce Jorda Mark L Gonzalgo Source Type: research
Splicing targeting drugs highlight intron retention as an actionable vulnerability in advanced prostate cancer
CONCLUSIONS: Our study uncovers intron retention as an actionable vulnerability for advanced PC, which may be exploited to improve therapeutic management of this currently incurable disease.PMID:38413979 | PMC:PMC10898177 | DOI:10.1186/s13046-024-02986-0 (Source: Clinical Prostate Cancer)
Source: Clinical Prostate Cancer - February 27, 2024 Category: Cancer & Oncology Authors: Chiara Naro Ambra Antonioni Vanessa Medici Cinzia Caggiano Ariane Jolly Pierre de la Grange Pamela Bielli Maria Paola Paronetto Claudio Sette Source Type: research
Cutaneous Metastasis From Prostate Cancer on Posttherapeutic 177Lu-Prostate-Specific Membrane Antigen Scan
Clin Nucl Med. 2024 Feb 27. doi: 10.1097/RLU.0000000000005130. Online ahead of print.ABSTRACTIn this note, we aim to present a patient with a known case of prostate cancer with widespread metastasis to the skeleton and liver who has undergone several cycles of chemoradiotherapy. The patient received 2 doses of 177Lu-prostate-specific membrane antigen therapy, in which several zones of uptake were detected on the thoracic wall compatible with cutaneous metastatic lesions of prostate cancer.PMID:38409757 | DOI:10.1097/RLU.0000000000005130 (Source: Clinical Prostate Cancer)
Source: Clinical Prostate Cancer - February 27, 2024 Category: Cancer & Oncology Authors: Mohammad Taghavi Reyhane Ahmadi Mohsen Qutbi Source Type: research
68Ga-PSMA Uptake in the Testis: Two Different Patients With Two Different Diagnosis
Clin Nucl Med. 2024 Feb 27. doi: 10.1097/RLU.0000000000005128. Online ahead of print.ABSTRACTAlthough abnormal 68Ga-PSMA uptake in the prostate and its metastases can be seen in a variety of diseases, it is rare to see in the testis. In these 2 cases, 68Ga-PSMA PET/CT revealed unilateral 68Ga-PSMA uptake in the testis of 2 patients. One of these patients was diagnosed with testis metastases from prostate cancer after an orchiectomy. The other patient was diagnosed with an orchitis. 68Ga-PSMA uptake should be considered as an infection, as well as a malignancy in the initial differential diagnosis.PMID:38409760 | DOI:10.109...
Source: Clinical Prostate Cancer - February 27, 2024 Category: Cancer & Oncology Authors: Merve Nida Calderon Tobar Hasan Önner Source Type: research
Dual 177Lu-Prostate-Specific Membrane Antigen and 177Lu-DOTATATE Therapy in Metastatic Castration-Resistant Prostate Cancer With Neuroendocrine Differentiation
We present an 87-year-old man diagnosed with prostate cancer and neuroendocrine differentiation, posttherapy results to consecutive 177Lu-prostate-specific membrane antigen and 177Lu-DOTATATE. Despite hormonal therapy and chemoradiotherapy, the patient progressed rapidly, and multiple liver and bone metastases showed regression after 177Lu-prostate-specific membrane antigen and 177Lu-DOTATATE treatment. Prostate cancer with neuroendocrine differentiation is resistant to treatments; however, treatment with the combination of 177Lu-DOTATATE therapy may be promising.PMID:38409763 | DOI:10.1097/RLU.0000000000005131 (Source: Cl...
Source: Clinical Prostate Cancer - February 27, 2024 Category: Cancer & Oncology Authors: Ediz Beyhan Özge Erol Fenercioğlu Rahime Şahin Tevfik Fikret Çermik Nurhan Erg ül Source Type: research
MRI-based radiomic features for identifying recurrent prostate cancer after proton radiation therapy
CONCLUSIONS: Our proof-of-concept study demonstrates the potential of using radiomic features as part of the differential diagnosis of PCa on mpMRI following proton therapy. The results need to be validated in a larger cohort.PMID:38409947 | DOI:10.1002/acm2.14293 (Source: Clinical Prostate Cancer)
Source: Clinical Prostate Cancer - February 27, 2024 Category: Cancer & Oncology Authors: Kazim Z Gumus Samuel Serrano Contreras Mohammed Al-Toubat Ira Harmon Mauricio Hernandez Savas Ozdemir Sindhu Kumar Nurcan Yuruk Mutlu Mete K C Balaji Mark Bandyk Dheeraj R Gopireddy Source Type: research
Radical prostatectomy cancer grade and percentage of Gleason pattern 4 estimated by global vs individual tumor grading correlate differently with the risk of biochemical recurrence in Grade Group 2 and 3 cancers
CONCLUSIONS: Grade Group, GP4%, and margin status derived by global vs individual tumor grading predict postoperative biochemical recurrence statistically significantly differently. This difference has important implications if results derived from cohorts graded using different methods are compared.PMID:38412318 | DOI:10.1093/ajcp/aqae003 (Source: Clinical Prostate Cancer)
Source: Clinical Prostate Cancer - February 27, 2024 Category: Cancer & Oncology Authors: Oleksandr N Kryvenko Jonathan I Epstein Ali Merhe Oleksii A Iakymenko Ricardo De Almeida E Silva Dimple Kumar Chanamolu Laurence M Briski Deukwoo Kwon Ivan Nemov Sanoj Punnen Alan Pollack Radka Stoyanova Dipen J Parekh Merce Jorda Mark L Gonzalgo Source Type: research
Splicing targeting drugs highlight intron retention as an actionable vulnerability in advanced prostate cancer
CONCLUSIONS: Our study uncovers intron retention as an actionable vulnerability for advanced PC, which may be exploited to improve therapeutic management of this currently incurable disease.PMID:38413979 | DOI:10.1186/s13046-024-02986-0 (Source: Clinical Prostate Cancer)
Source: Clinical Prostate Cancer - February 27, 2024 Category: Cancer & Oncology Authors: Chiara Naro Ambra Antonioni Vanessa Medici Cinzia Caggiano Ariane Jolly Pierre de la Grange Pamela Bielli Maria Paola Paronetto Claudio Sette Source Type: research
